|

PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

RECRUITINGPhase 4Sponsored by Kindai University
Actively Recruiting
PhasePhase 4
SponsorKindai University
Started2023-02-28
Est. completion2025-01-04
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05709626

Summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)
* STEMI patients
* Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months

Exclusion Criteria:

* Patients taking anticoagulants
* Patients under 18 years old
* Patients with less than 1 year prognosis
* Patients participating in other intervention studies

Conditions2

Heart DiseaseST-segment Elevation Myocardial Infarction (STEMI)

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.